Polish experience in Peptide receptor radionuclide therapy

Area of Science:

• Oncology
• Nuclear Medicine
• Radiopharmacology

Background:

• Neuroendocrine tumors (NETs) are a heterogeneous group of malignancies.
• Metastatic or inoperable NETs often require systemic treatment options.
• Peptide receptor radionuclide therapy (PRRT) utilizes radiolabeled somatostatin analogs to target NET cells.

Purpose of the Study:

• To evaluate the efficacy and safety of PRRT in a Polish patient cohort.
• To compare outcomes between single-isotope and tandem PRRT regimens.
• To assess progression-free survival (PFS), overall survival (OS), and toxicity profiles.

Main Methods:

• Retrospective analysis of 358 patients treated with PRRT from April 2004 to December 2010.
• Therapies included (90)Y-DOTATATE, (177)Lu-DOTATATE, and tandem (90)Y/(177)Lu-DOTATATE.
• Patient outcomes and adverse events were monitored.

Main Results:

• (90)Y-DOTATATE therapy showed PFS/TTP of 17-44 months and OS of 22-34.2 months.
• Tandem (90)Y/(177)Lu-DOTATATE therapy resulted in longer PFS/TTP (24.2-28.3 months) and OS (49.8-52.8 months).
• PRRT was generally well-tolerated; grade 3/4 hematological and renal toxicity was primarily observed with (90)Y-DOTATATE.

Conclusions:

• PRRT is an effective and safe treatment for metastatic or inoperable NETs.
• Tandem (90)Y/(177)Lu-DOTATATE therapy demonstrated superior overall survival compared to single-isotope treatments.
• Hematological toxicity was rare, and significant renal toxicity was associated mainly with (90)Y-DOTATATE.